The effects of hemodialysis on blood glutamate levels in chronic renal failure: Implementation for neuroprotection

Journal of Critical Care

Volumn 27, Issue 6, 2012, Pages 743.e1-743.e7

  Rogachev, Boris ^a   Ohayon, Sharon ^a   Saad, Amit ^b   Vorobiovsky, Victoria ^a   Gruenbaum, Benjamin F ^a   Leibowitz, Akiva ^a   Boyko, Matthew ^a   Shapira, Yoram ^a   Shnaider, Alla ^a   Zlotnik, Moshe ^a   Azab, Abed N ^a   Zlotnik, Alexander ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

Author keywords

Brain injury; Glutamate; Glutamate oxaloacetate transaminase (GOT); Glutamate pyruvate transaminase (GPT); Hemodialysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; GLUTAMIC ACID; UREA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUTAMIC ACID BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; PLASMA CLEARANCE; STAGING; UREA BLOOD LEVEL;

EID: 84870665439     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.07.002     Document Type: Article

References (56)

1. Castillo J., Davalos A., Naveiro J., et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996, 27:1060-1065.
2. Castillo J., Davalos A., Noya M. Progression of ischaemic stroke and excitotoxic amino acids. Lancet 1997, 349:79-83.
3. Johnston M.V., Trescher W.H., Ishida A., et al. Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr Res 2001, 49:735-741.
4. Zauner A., Bullock R., Kuta A.J., et al. Glutamate release and cerebral blood flow after severe human head injury. Acta Neurochir Suppl 1996, 67:40-44.
5. Campos F., Sobrino T., Ramos-Cabrer P., et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab 2011.
6. Campos F., Sobrino T., Ramos-Cabrer P., et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 2011.
7. Campos F., Rodriguez-Yanez M., Castellanos M., et al. Blood levels of glutamate oxaloacetate transaminase are stronger associated with good outcome in acute ischemic stroke than glutamate pyruvate transaminase. Clin Sci (Lond) 2011.
8. Hardingham G.E., Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci 2003, 26:81-89.
9. Ikonomidou C., Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol 2002, 1:383-386.
10. Morris G.F., Juul N., Marshall S.B., et al. Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial. Neurosurgery 1998, 43:1369-1372. discussion 1372-1364.
11. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995, 26:503-513.
12. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006, 6:53-60.
13. O'Kane R.L., Martinez-Lopez I., DeJoseph M.R., et al. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999, 274:31891-31895.
14. Teichberg V.I., Cohen-Kashi-Malina K., Cooper I., et al. Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 2009, 158:301-308.
15. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
16. Berl S., Lajtha A., Waelsch H. Amino acid and protein metabolism of the brain. VI. Cerebral compartments of glutamic acid metabolism. J Neurochem 1961, 7:186-197.
17. Berl S., Takagaki G., Clarke D.D., et al. Metabolic compartments in vivo. Ammonia and glutamic acid metabolism in brain and liver. J Biol Chem 1962, 237:2562-2569.
18. Gottlieb M., Wang Y., Teichberg V.I. Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 2003, 87:119-126.
19. Zlotnik A., Gruenbaum S.E., Artru A.A., et al. The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 2009, 21:235-241.
20. Zlotnik A., Gurevich B., Cherniavsky E., et al. The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 2008, 33:1044-1050.
21. Zlotnik A., Gurevich B., Tkachov S., et al. Brain neuroprotection by scavenging blood glutamate. Exp Neurol 2007, 203:213-220.
22. Zlotnik A., Gurevich B., Cherniavsky E., et al. The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 2007.
23. Graham L.T. Aprison MH: Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods. Anal Biochem 1966, 15:487-497.
24. Zlotnik A., Gruenbaum B.F., Mohar B., et al. The effects of estrogen and progesterone on blood glutamate levels: evidence from changes of blood glutamate levels during the menstrual cycle in women. Biol Reprod 2010, 2010.
25. Zlotnik A, Klin Y, Gruenbaum BF, et al. The activation of beta2-adrenergic receptors in naive rats causes a reduction of blood glutamate levels: relevance to stress and neuroprotection. Neurochem Res.
26. Zlotnik A., Ohayon S., Artru A.A., et al. 2008, Orlando, FL, USA.
27. Divino Filho J.C., Barany P., Stehle P., et al. Free amino-acid levels simultaneously collected in plasma, muscle, and erythrocytes of uraemic patients. Nephrol Dial Transplant 1997, 12:2339-2348.
28. Ikizler T.A., Flakoll P.J., Parker R.A., et al. Amino acid and albumin losses during hemodialysis. Kidney Int 1994, 46:830-837.
29. Choi JY, Yoon YJ, Choi HJ, et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant.
30. Divino Filho J.C., Hazel S.J., Furst P., et al. Glutamate concentration in plasma, erythrocyte and muscle in relation to plasma levels of insulin-like growth factor (IGF)-I, IGF binding protein-1 and insulin in patients on haemodialysis. J Endocrinol 1998, 156:519-527.
31. Giordano C., De Santo N.G., Capodicasa G., et al. Amino acid losses during CAPD. Clin Nephrol 1980, 14:230-232.
32. Kopple J.D., Blumenkrantz M.J., Jones M.R., et al. Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis. Am J Clin Nutr 1982, 36:395-402.
33. Wolfson M., Jones M.R., Kopple J.D. Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 1982, 21:500-506.
34. Gil H.W., Yang J.O., Lee E.Y., et al. The effect of dialysis membrane flux on amino acid loss in hemodialysis patients. J Korean Med Sci 2007, 22:598-603.
35. Bergstrom J. Protein catabolic factors in patients on renal replacement therapy. Adv Exp Med Biol 1989, 260:1-9.
36. Garred L.J., Canaud B., Bosc J.Y., et al. Urea rebound and delivered Kt/V determination with a continuous urea sensor. Nephrol Dial Transplant 1997, 12:535-542.
37. Castro M.C., Romao J.E., Marcondes M. Measurement of blood urea concentration during haemodialysis is not an accurate method to determine equilibrated post-dialysis urea concentration. Nephrol Dial Transplant 2001, 16:1814-1817.
38. Soupart A., Silver S., Schrooeder B., et al. Rapid (24-hour) reaccumulation of brain organic osmolytes (particularly myo-inositol) in azotemic rats after correction of chronic hyponatremia. J Am Soc Nephrol 2002, 13:1433-1441.
39. + and glutamate accumulation during osmotic adaptation of Escherichia coli. J Biol Chem 1994, 269:1911-1917.
40. Cohen G.A., Goffinet J.A., Donabedian R.K., et al. Observations on decreased serum glutamic oxaloacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976, 84:275-280.
41. Crawford D.R., Reyna R.S., Weiner M.W. Effects of in vivo and in vitro dialysis on plasma transaminase activity. Nephron 1978, 22:418-422.
42. Boyko M., Zlotnik A., Gruenbaum B.F., et al. An experimental model of focal ischemia using an internal carotid artery approach. J Neurosci Methods 2010, 193:246-253.
43. Zlotnik A, Ohayon S, Gruenbaum BF, et al. Determination of factors affecting glutamate concentrations in the whole blood of healthy human volunteers. J Neurosurg Anesthesiol 23:45-49.
44. Zlotnik A., Gruenbaum E.S., Artru A.A., et al. 2009, New-Orleans, LA, USA.
45. Zlotnik A., Gruenbaum B.F., Mohar B., et al. The effects of estrogen and progesterone on blood glutamate levels: evidence from changes of blood glutamate levels during the menstrual cycle in women. Biol Reprod 2011, 84:581-586.
46. Boyko M., Zlotnik A., Gruenbaum B.F., et al. Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. Eur J Neurosci 2011, 34:1432-1441.
47. Zlotnik A., Klin Y., Kotz R., et al. Regulation of blood l-glutamate levels by stress as a possible brain defense mechanism. Exp Neurol 2010.
48. Teichberg V.I., Cohen-Kashi-Malina K., Cooper I., et al. Homeostasis of glutamate in brain fluids: An accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 2008, [Epub ahead of print].
49. Zlotnik A., Sinelnikov I., Dubilet M., et al. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. Anesthesiology 2011, In press.
50. Zlotnik A., Klin Y., Gruenbaum B.F., et al. The activation of beta2-adrenergic receptors in naive rats causes a reduction of blood glutamate levels: relevance to stress and neuroprotection. Neurochem Res 2011, 36:732-738.
51. Zlotnik A., Leibowitz A., Gurevich B., et al. Effect of estrogens on blood glutamate levels in relation to neurological outcome after TBI in male rats. Intensive Care Med 2012, 38:137-144.
52. Nagy D., Knapp L., Marosi M., et al. Effects of blood glutamate scavenging on cortical evoked potentials. Cell Mol Neurobiol 2010, 30:1101-1106.
53. Marosi M., Fuzik J., Nagy D., et al. Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion. Eur J Pharmacol 2009, 604:51-57.
54. McIntyre C.W. Recurrent circulatory stress: the dark side of dialysis. Semin Dial 2010, 23:449-451.
55. Pakfetrat M., Roozbeh J., Malekmakan L., et al. Relation of serum albumin and C-reactive protein to hypotensive episodes during hemodialysis sessions. Saudi J Kidney Dis Transpl 2010, 21:707-711.
56. Sulowicz W., Radziszewski A. Dialysis induced hypotension-a serious clinical problem in renal replacement therapy. Med Pregl 2007, 60(Suppl 2):14-20.